G1 Therapeutics Provides Third Quarter 2022 Financial
- Achieved $23.6 million in Total Revenue in the Third Quarter of 2022 Including $8.3 million in Net Revenue from Sales of COSELA® (trilaciclib) - -...
Source: globenewswire.com
📰 Encouraging Initial Data News
Encouraging Initial Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Encouraging Initial Data. Real-time updates on events, politics, business and more.